Want to see DHR full AI Analyst Report?
DHR Stock Chart & Stats
$194.75
-$1.72(-0.72%)
At close: 4:00 PM EST
$194.75
-$1.72(-0.72%)
Day’s Range― - ―
52-Week Range$160.93 - $242.80
Previous CloseN/A
Volume816.38K
Average Volume (3M)3.81M
Market Cap
$144.26B
Enterprise Value$143.09K
Total Cash (Recent Filing)$5.70B
Total Debt (Recent Filing)$18.48B
Price to Earnings (P/E)39.3
Beta0.75
Next Earnings
Jul 21, 2026EPS Estimate
1.84Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)5.19
Shares Outstanding707,770,600
10 Day Avg. Volume3,760,415
30 Day Avg. Volume3,814,443
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$230.32Price Target Upside18.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)8.45
Revenue Forecast (FY)$25.62B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowConsistently high free cash flow and strong conversion support durable capital allocation: funds for R&D, bolt-on M&A, dividends and buybacks. Robust FCF (> $5B guidance) provides flexibility versus peers and cushions the business against cyclical equipment timing and macro shocks.
Recurring Consumables & ServicesA lifecycle model—instrument sales followed by recurring consumables, reagents and services—generates predictable, high-margin annuity revenue. This reduces revenue volatility, supports sustained margins and raises switching costs in regulated lab and bioprocess workflows over multi-year horizons.
Strategic Masimo Deal And SynergiesCompleting Masimo expands patient-monitoring and sensor tech, broadening diagnostics and recurring consumable opportunities. Expected near-term accretion and targeted multi-year ROIC plus quantifiable synergies enhance cross-sell potential and long-term product portfolio diversification.
Bears Say
China Diagnostics Pricing HeadwindsVolume-based procurement and reimbursement changes in China have structurally lowered pricing and created a material ( ~$75M–$100M ) headwind. Persistent regulatory pricing pressure can compress margins and reduce a previously high-growth addressable market for clinical consumables.
Weaker Capital Efficiency Vs Prior CycleMaterial decline in ROE and narrower net margins versus earlier cycles implies the company now converts capital to profit less efficiently. That reduces long-term earnings power and puts pressure on returns to shareholders unless operational margins or asset efficiency improve sustainably.
Lumpy Equipment Revenue And Instrument SoftnessLarge order-to-revenue timing and customer readiness create revenue recognition volatility. Combined with muted academic and instrumentation demand, this produces uneven top-line and margin swings across reporting periods, complicating visibility into durable organic growth trends.
Danaher News
DHR FAQ
What was Danaher Corporation’s price range in the past 12 months?
Danaher Corporation lowest stock price was $160.93 and its highest was $242.80 in the past 12 months.
What is Danaher Corporation’s market cap?
Danaher Corporation’s market cap is $144.26B.
When is Danaher Corporation’s upcoming earnings report date?
Danaher Corporation’s upcoming earnings report date is Jul 21, 2026 which is in 2 days.
How were Danaher Corporation’s earnings last quarter?
Danaher Corporation released its earnings results on Apr 21, 2026. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.935 by $0.125.
Is Danaher Corporation overvalued?
According to Wall Street analysts Danaher Corporation’s price is currently Undervalued.
Does Danaher Corporation pay dividends?
Danaher Corporation pays a Quarterly dividend of $0.4 which represents an annual dividend yield of 0.53%. See more information on Danaher Corporation dividends here
What is Danaher Corporation’s EPS estimate?
Danaher Corporation’s EPS estimate is 1.84.
How many shares outstanding does Danaher Corporation have?
Danaher Corporation has 707,770,600 shares outstanding.
What happened to Danaher Corporation’s price movement after its last earnings report?
Danaher Corporation reported an EPS of $2.06 in its last earnings report, beating expectations of $1.935. Following the earnings report the stock price went down -0.491%.
Which hedge fund is a major shareholder of Danaher Corporation?
Currently, no hedge funds are holding shares in DHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$230.32 (18.26% Upside)
$230.32 (18.26% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $237.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.41%
12-Months-Change
Fundamentals
Return on Equity
7.06%
Trailing 12-Months
Asset Growth
5.60%
Trailing 12-Months
Company Description
Danaher Corporation
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
DHR Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics

DHR Stock 12 Month Forecast
Average Price Target
$230.32
▲(18.26% Upside)
Technical Analysis
Ownership Overview
3.89% Insiders
26.57% Mutual Funds
0.27% Other Institutional Investors
49.73% Public Companies and Individual Investors












